Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences
09/02/2021 - 07:30 AM
BOSTON --(BUSINESS WIRE)--
Ironwood Pharmaceuticals, Inc.
2021 Wells Fargo Healthcare Conference on Friday, September 10, 2021 at 2:00 p.m. ET
Morgan Stanley 19th Annual Global Healthcare Conference on Monday, September 13, 2021 at 2:45 p.m. ET
A live webcast of Ironwood’s fireside chats will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com . To access the webcasts, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Ironwood’s website for 14 days following the conference.
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD) is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. We discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
Ironwood was founded in 1998 and is headquartered in Boston, Mass. For more information, please visit our website at www.ironwoodpharma.com or www.twitter.com/ironwoodpharma ; information that may be important to investors will be routinely posted in both these locations.
View source version on businesswire.com : https://www.businesswire.com/news/home/20210902005017/en/
Investors:
Matt Roache , 617-621-8395
mroache@ironwoodpharma.com
Source: Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals Inc
IRWD Rankings
#3314 Ranked by Stock Gains
IRWD Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Boston
About IRWD
ironwood pharmaceuticals (nasdaq: irwd) is focused on creating medicines that make a difference for patients, building value to earn the continued support of our fellow shareholders, and empowering our passionate team to keep doing these two things again and again as we continue to build a leading gastrointestinal therapeutics company. we discovered, developed and are commercializing a medicine for the treatment of adults suffering from irritable bowel syndrome with constipation (ibs-c) or chronic idiopathic constipation (cic). we are also developing a rich pipeline of programs seeking to address patient needs across the upper and lower gastrointestinal tract. our pipeline priorities include exploring further opportunities for our lead medicine, as well as leveraging our therapeutic expertise in gastrointestinal disorders and our pharmacologic expertise in guanylate cyclases to advance multiple investigational medicines. ironwood was founded in 1998 out of the whitehead institute for b
